ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
December 07, 2021Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab... -
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
September 28, 2021Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab...
Pharma Sources Insight January 2025
